Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study seeks to integrate preoperative imaging data with intraoperative metabolic feedback to dynamically guide biopsy core placement in prostate cancer patients. The approach uses an intelligent system to adjust sampling decisions during the procedure based on real-time information. The study focuses on individualized sampling to potentially improve diagnostic accuracy while addressing safety and feasibility in an urban Chinese hospital network. Participants are men aged 55 and older undergoing a biopsy with available PSA measurements and mpMRI results within the prior month. Exclusion criteria target non-prostatic malignancies, concurrent cancers that affect imaging, and severe physiological compromise.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥55 years;
2. Indication for prostate biopsy;
3. Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy.

Exclusion Criteria:

1. Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma;
2. Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer);
3. Cachexia or organ function decompensation.

Where it's running

• Minhang Hospital, Fudan University
  Shanghai, China Recruiting
• Shanghai Geriatric Medical Center
  Shanghai, China Recruiting
• Xuhui Hospital, Fudan University
  Shanghai, China Recruiting
• Zhongshan Hospital, Fudan University
  Shanghai, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• Using PSMA PET with MRI to watch for prostate cancer returning after focal therapy

  We will try adding a PSMA PET scan to routine MRI follow-up to see if it finds prostate cancer coming back sooner in men who had focal (partial gland) therapy.

  Recruiting University of Chicago · Chicago, Illinois · NCT07115914

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• Hugo Robotic Prostatectomy in an Ambulatory Surgery Center

  This study tests the use of the Hugo robotic system for prostate removal in adult men treated at an outpatient surgical center.

  Recruiting Central Ohio Urology Group · Columbus, Ohio · NCT07875192

• miRNA panel test to help diagnose prostate cancer

  A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.

  Recruiting RenJi Hospital · Shanghai · NCT07755592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.